← Leaderboards
Silvio Antoniak
Univ Of North Carolina Chapel Hill
$4,198,060
Attributed
$4,198,060
Total exposure
2
Grants
2
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $952.5K · FY2018–23$1M$750K$500K$250K$0
'18
'19
'20
'21
'22
'23
Funding mix
By agency
NIH$4,198,060 · 2
By mechanism
R01$4,198,060 · 2
Top collaborators
No co-investigators on record.
Most similar at Univ Of North Carolina Chapel Hill
Same institution · by research overlap
- Nigel Mackman$23,794,157
- Rafal L Pawlinski$8,739,544
- Albert Phillip Owens III$7,520,869
- Nigel S Key$14,906,926
- Erica M Sparkenbaugh$2,021,037
Others in their field
Other Emerging Leaders on “Cardiac”
- Ionut Bebu · George Washington University$14,731,026
- Barbara Halina Braffett · George Washington University$14,731,026
- Jeremy James Martinson · University Of Pittsburgh At Pittsburgh$14,031,836
- Romergryko Geocadin · University Of Michigan At Ann Arbor$9,719,654
- Federico Cividini · Cardiac Rsk3 Inhibitors, Llc$9,716,114
- Nobuyuki Ishibashi · Children'S Research Institute$9,208,869
Research focus
CardiacIn VitroPathologicCellsPathologyMouse ModelFibroblastsNovel TherapeuticsPathway InteractionsProteinase-Activated ReceptorsImproved OutcomePeptide HydrolasesFda ApprovedLeadInhibitor/AntagonistBlood Coagulation FactorInfectionInflammationAdaptive Immune ResponseAntiviral ResponseInflammatoryCell TypeHeartFactor Xa
Grant awards (9)
PAR1 as a Therapeutic Target in Doxorubicin-induced Cardiotoxicity$563,715
R01 · FY2023 · HL · contact PI
PAR1 as a Therapeutic Target in Doxorubicin-induced Cardiotoxicity$563,715
R01 · FY2022 · HL · contact PI
Inhibition of PAR2 as therapeutic approach to enhance anti-viral immune responses$388,750
R01 · FY2022 · HL · contact PI
PAR1 as a Therapeutic Target in Doxorubicin-induced Cardiotoxicity$563,715
R01 · FY2021 · HL · contact PI
Inhibition of PAR2 as therapeutic approach to enhance anti-viral immune responses$388,750
R01 · FY2021 · HL · contact PI
PAR1 as a Therapeutic Target in Doxorubicin-induced Cardiotoxicity$563,165
R01 · FY2020 · HL · contact PI
Inhibition of PAR2 as therapeutic approach to enhance anti-viral immune responses$388,750
R01 · FY2020 · HL · contact PI
Inhibition of PAR2 as therapeutic approach to enhance anti-viral immune responses$388,750
R01 · FY2019 · HL · contact PI
Inhibition of PAR2 as therapeutic approach to enhance anti-viral immune responses$388,750
R01 · FY2018 · HL · contact PI